Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, José Antônio Sanches et al.|The Lancet|2017Cited by 580
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant ResearchSally Arai, Yoshiko Atsuta, Mukta Arora et al.|Biology of Blood and Marrow Transplantation|2014Cited by 435
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 BlockadeTessa Gargett, Michael P. Brown, Wenbo Yu et al.|Molecular Therapy|2016Cited by 358
Gaq signaling is required for the maintenance of MLL-AF9-induced acute myeloid leukemiaJodi Lynch, Jenny Wang, Hangyu Yi et al.|Leukemia|2016Cited by 10